| MeSH term | MeSH ID | Detail |
|---|---|---|
| Cerebrovascular Disorders | D002561 | 25 associated lipids |
| Polycythemia Vera | D011087 | 13 associated lipids |
| Hyperlipidemias | D006949 | 73 associated lipids |
| Blood Platelet Disorders | D001791 | 12 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Renal Artery Obstruction | D012078 | 8 associated lipids |
| Atrial Fibrillation | D001281 | 16 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Death, Sudden, Cardiac | D016757 | 12 associated lipids |
| Hypoalphalipoproteinemias | D052456 | 5 associated lipids |
11-dehydro-TXB2
11-dehydro-txb2 is a lipid of Fatty Acyls (FA) class. 11-dehydro-txb2 is associated with abnormalities such as endothelial dysfunction, Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis and Chronic ischemic heart disease NOS. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and Lipid Peroxidation. The associated genes with 11-dehydro-TXB2 are PTGS2 gene.
Cross Reference
Introduction
To understand associated biological information of 11-dehydro-TXB2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 11-dehydro-TXB2?
11-dehydro-TXB2 is suspected in endothelial dysfunction, Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis, Chronic ischemic heart disease NOS, Diabetes Mellitus and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 11-dehydro-TXB2
PubChem Associated disorders and diseases
What pathways are associated with 11-dehydro-TXB2
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 11-dehydro-TXB2?
There are no associated biomedical information in the current reference collection.
What functions are associated with 11-dehydro-TXB2?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 11-dehydro-TXB2?
There are no associated biomedical information in the current reference collection.
What genes are associated with 11-dehydro-TXB2?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 11-dehydro-TXB2?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with 11-dehydro-TXB2
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ross S et al. | Association of cyclooxygenase-2 genetic variant with cardiovascular disease. | 2014 | Eur. Heart J. | pmid:24796340 |
| DeFilippis AP et al. | Fatty acids and TxA(2) generation, in the absence of platelet-COX-1 activity. | 2014 | Nutr Metab Cardiovasc Dis | pmid:24370448 |
| Gonçalves LH et al. | Acetylsalicylic acid therapy: influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels. | 2014 | Clin. Chim. Acta | pmid:24316050 |
| Dudley A et al. | Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin. | 2013 Jan-Feb | J. Vet. Intern. Med. | pmid:23278865 |
| Gremmel T et al. | Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy. | 2013 | J. Atheroscler. Thromb. | pmid:23739624 |
| Nakamura A et al. | Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. | 2013 | Circ. J. | pmid:23676973 |
| Vazzana N et al. | Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype. | 2013 | J Am Heart Assoc | pmid:23557750 |
| DeFilippis AP et al. | Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction. | 2013 | Circ. J. | pmid:23985963 |
| Kapłon-Cieślicka A et al. | Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. | 2013 | Kardiol Pol | pmid:24065375 |
| d'Emmanuele di Villa Bianca R et al. | Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. | 2013 | Proc. Natl. Acad. Sci. U.S.A. | pmid:24019484 |